Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 85 to 94 of 94 entries
Sorted by: Best Match Show Resources per page
Species distribution and antifungal susceptibility patterns of Aspergillus isolates from clinical specimens and soil samples in Mexico.

Medical mycology

Treviño-Rangel RJ, Villanueva-Lozano H, Bonifaz A, Castañón-Olivares LR, Andrade A, Becerril-García MA, Martínez-Reséndez MF, Ayala-Gaytán J, Montoya AM, González GM.
PMID: 34021564
Med Mycol. 2021 Oct 04;59(10):1006-1014. doi: 10.1093/mmy/myab031.

This study aimed to assess the species distribution and antifungal susceptibility patterns of 200 strains of Aspergillus isolated from clinical specimens (n = 146) and soil samples (n = 54) in Mexico. ITS, β-tubulin, and calmodulin DNA sequencing was...

Cite
Treviño-Rangel RJ, Villanueva-Lozano H, Bonifaz A, et al. Species distribution and antifungal susceptibility patterns of Aspergillus isolates from clinical specimens and soil samples in Mexico. Med Mycol. 2021;59(10):1006-1014doi: 10.1093/mmy/myab031.
Treviño-Rangel, R. J., Villanueva-Lozano, H., Bonifaz, A., Castañón-Olivares, L. R., Andrade, A., Becerril-García, M. A., Martínez-Reséndez, M. F., Ayala-Gaytán, J., Montoya, A. M., & González, G. M. (2021). Species distribution and antifungal susceptibility patterns of Aspergillus isolates from clinical specimens and soil samples in Mexico. Medical mycology, 59(10), 1006-1014. https://doi.org/10.1093/mmy/myab031
Treviño-Rangel, Rogelio de J, et al. "Species distribution and antifungal susceptibility patterns of Aspergillus isolates from clinical specimens and soil samples in Mexico." Medical mycology vol. 59,10 (2021): 1006-1014. doi: https://doi.org/10.1093/mmy/myab031
Treviño-Rangel RJ, Villanueva-Lozano H, Bonifaz A, Castañón-Olivares LR, Andrade A, Becerril-García MA, Martínez-Reséndez MF, Ayala-Gaytán J, Montoya AM, González GM. Species distribution and antifungal susceptibility patterns of Aspergillus isolates from clinical specimens and soil samples in Mexico. Med Mycol. 2021 Oct 04;59(10):1006-1014. doi: 10.1093/mmy/myab031. PMID: 34021564.
Copy Download .nbib Format: NLM
Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients.

ClinicoEconomics and outcomes research : CEOR

Grau S, Pozo JC, Romá E, Salavert M, Barrueta JA, Peral C, Rodriguez I, Rubio-Rodríguez D, Rubio-Terrés C.
PMID: 26508881
Clinicoecon Outcomes Res. 2015 Oct 13;7:527-35. doi: 10.2147/CEOR.S91587. eCollection 2015.

OBJECTIVE: To estimate the cost-effectiveness of three echinocandins (anidulafungin, caspofungin, and micafungin) and generic fluconazole in the treatment of nonneutropenic adult patients with candidemia and/or invasive candidiasis in intensive care units in Spain.MATERIALS AND METHODS: A decision-tree model was...

Cite
Grau S, Pozo JC, Romá E, et al. Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients. Clinicoecon Outcomes Res. 2015;7:527-35doi: 10.2147/CEOR.S91587.
Grau, S., Pozo, J. C., Romá, E., Salavert, M., Barrueta, J. A., Peral, C., Rodriguez, I., Rubio-Rodríguez, D., & Rubio-Terrés, C. (2015). Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients. ClinicoEconomics and outcomes research : CEOR, 7527-35. https://doi.org/10.2147/CEOR.S91587
Grau, S, et al. "Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients." ClinicoEconomics and outcomes research : CEOR vol. 7 (2015): 527-35. doi: https://doi.org/10.2147/CEOR.S91587
Grau S, Pozo JC, Romá E, Salavert M, Barrueta JA, Peral C, Rodriguez I, Rubio-Rodríguez D, Rubio-Terrés C. Cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients. Clinicoecon Outcomes Res. 2015 Oct 13;7:527-35. doi: 10.2147/CEOR.S91587. eCollection 2015. PMID: 26508881; PMCID: PMC4610791.
Copy Download .nbib Format: NLM
Diversity and antifungal susceptibility of Norwegian Candida glabrata clinical isolates.

Journal of oral microbiology

Andersen KM, Kristoffersen AK, Ingebretsen A, Vikholt KJ, Örtengren UT, Olsen I, Enersen M, Gaustad P.
PMID: 26861194
J Oral Microbiol. 2016 Feb 08;8:29849. doi: 10.3402/jom.v8.29849. eCollection 2016.

BACKGROUND: Increasing numbers of immunocompromised patients have resulted in greater incidence of invasive fungal infections with high mortality. Candida albicans infections dominate, but during the last decade, Candida glabrata has become the second highest cause of candidemia in the...

Cite
Andersen KM, Kristoffersen AK, Ingebretsen A, et al. Diversity and antifungal susceptibility of Norwegian Candida glabrata clinical isolates. J Oral Microbiol. 2016;8:29849doi: 10.3402/jom.v8.29849.
Andersen, K. M., Kristoffersen, A. K., Ingebretsen, A., Vikholt, K. J., Örtengren, U. T., Olsen, I., Enersen, M., & Gaustad, P. (2016). Diversity and antifungal susceptibility of Norwegian Candida glabrata clinical isolates. Journal of oral microbiology, 829849. https://doi.org/10.3402/jom.v8.29849
Andersen, Kari-Mette, et al. "Diversity and antifungal susceptibility of Norwegian Candida glabrata clinical isolates." Journal of oral microbiology vol. 8 (2016): 29849. doi: https://doi.org/10.3402/jom.v8.29849
Andersen KM, Kristoffersen AK, Ingebretsen A, Vikholt KJ, Örtengren UT, Olsen I, Enersen M, Gaustad P. Diversity and antifungal susceptibility of Norwegian Candida glabrata clinical isolates. J Oral Microbiol. 2016 Feb 08;8:29849. doi: 10.3402/jom.v8.29849. eCollection 2016. PMID: 26861194; PMCID: PMC4748091.
Copy Download .nbib Format: NLM
Synergistic in-vitro antiviral effects of combination treatment using anidulafungin and T-1105 against Zika virus infection.

Antiviral research

Lu JW, Chen YC, Huang CK, Lin KC, Ho YJ.
PMID: 34648875
Antiviral Res. 2021 Nov;195:105188. doi: 10.1016/j.antiviral.2021.105188. Epub 2021 Oct 11.

Zika virus (ZIKV) has been the cause of some epidemics since 2007. The correlations of microcephaly and Guillain-Barré syndrome with ZIKV have been noticed. Unfortunately, researchers have yet to develop an effective vaccine or drug approved for ZIKV infection....

Cite
Lu JW, Chen YC, Huang CK, et al. Synergistic in-vitro antiviral effects of combination treatment using anidulafungin and T-1105 against Zika virus infection. Antiviral Res. 2021;195:105188doi: 10.1016/j.antiviral.2021.105188.
Lu, J. W., Chen, Y. C., Huang, C. K., Lin, K. C., & Ho, Y. J. (2021). Synergistic in-vitro antiviral effects of combination treatment using anidulafungin and T-1105 against Zika virus infection. Antiviral research, 195105188. https://doi.org/10.1016/j.antiviral.2021.105188
Lu, Jeng-Wei, et al. "Synergistic in-vitro antiviral effects of combination treatment using anidulafungin and T-1105 against Zika virus infection." Antiviral research vol. 195 (2021): 105188. doi: https://doi.org/10.1016/j.antiviral.2021.105188
Lu JW, Chen YC, Huang CK, Lin KC, Ho YJ. Synergistic in-vitro antiviral effects of combination treatment using anidulafungin and T-1105 against Zika virus infection. Antiviral Res. 2021 Nov;195:105188. doi: 10.1016/j.antiviral.2021.105188. Epub 2021 Oct 11. PMID: 34648875.
Copy Download .nbib Format: NLM
Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology.

Therapeutic drug monitoring

Kim HY, Baldelli S, Märtson AG, Stocker S, Alffenaar JW, Cattaneo D, Marriott DJ.
PMID: 34654030
Ther Drug Monit. 2021 Nov 22; doi: 10.1097/FTD.0000000000000931. Epub 2021 Nov 22.

PURPOSE: Reduced exposure to echinocandins has been reported in specific patient populations, such as critically ill patients; however, fixed dosing strategies are still employed. The present review examines the accumulated evidence supporting echinocandin therapeutic drug monitoring (TDM) and summarizes...

Cite
Kim HY, Baldelli S, Märtson AG, et al. Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2021;doi: 10.1097/FTD.0000000000000931.
Kim, H. Y., Baldelli, S., Märtson, A. G., Stocker, S., Alffenaar, J. W., Cattaneo, D., & Marriott, D. J. (2021). Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic drug monitoring, . https://doi.org/10.1097/FTD.0000000000000931
Kim, Hannah Yejin, et al. "Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology." Therapeutic drug monitoring vol. (2021). doi: https://doi.org/10.1097/FTD.0000000000000931
Kim HY, Baldelli S, Märtson AG, Stocker S, Alffenaar JW, Cattaneo D, Marriott DJ. Therapeutic Drug Monitoring of the Echinocandin Antifungal Agents: Is There a Role in Clinical Practice? A Position Statement of the Anti-Infective Drugs Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Ther Drug Monit. 2021 Nov 22; doi: 10.1097/FTD.0000000000000931. Epub 2021 Nov 22. PMID: 34654030.
Copy Download .nbib Format: NLM
Anidulafungin versus fluconazole in the treatment of Candida albicans chorioretinitis.

Revista iberoamericana de micologia

Ruiz-Arranz C, Pérez-Blázquez E, De Pablo-Cabrera A, Ferro-Osuna M.
PMID: 34785085
Rev Iberoam Micol. 2021 Oct-Dec;38(4):188-191. doi: 10.1016/j.riam.2021.05.002. Epub 2021 Nov 14.

BACKGROUND: Candida albicans chorioretinitis is the most common cause of endogenous fungal endophthalmitis. Echinocandins are recommended as first-line therapy in the treatment of invasive candidiasis (IC), but in clinically stable patients with IC and endophthalmitis caused by Candida species...

Cite
Ruiz-Arranz C, Pérez-Blázquez E, De Pablo-Cabrera A, et al. Anidulafungin versus fluconazole in the treatment of Candida albicans chorioretinitis. Rev Iberoam Micol. 2021;38(4):188-191doi: 10.1016/j.riam.2021.05.002.
Ruiz-Arranz, C., Pérez-Blázquez, E., De Pablo-Cabrera, A., & Ferro-Osuna, M. (2021). Anidulafungin versus fluconazole in the treatment of Candida albicans chorioretinitis. Revista iberoamericana de micologia, 38(4), 188-191. https://doi.org/10.1016/j.riam.2021.05.002
Ruiz-Arranz, Celia, et al. "Anidulafungin versus fluconazole in the treatment of Candida albicans chorioretinitis." Revista iberoamericana de micologia vol. 38,4 (2021): 188-191. doi: https://doi.org/10.1016/j.riam.2021.05.002
Ruiz-Arranz C, Pérez-Blázquez E, De Pablo-Cabrera A, Ferro-Osuna M. Anidulafungin versus fluconazole in the treatment of Candida albicans chorioretinitis. Rev Iberoam Micol. 2021 Oct-Dec;38(4):188-191. doi: 10.1016/j.riam.2021.05.002. Epub 2021 Nov 14. PMID: 34785085.
Copy Download .nbib Format: NLM
A New Antifungal-Loaded Sol-Gel Can Prevent .

Antibiotics (Basel, Switzerland)

Garlito-Díaz H, Esteban J, Mediero A, Carias-Cálix RA, Toirac B, Mulero F, Faus-Rodrigo V, Jiménez-Morales A, Calvo E, Aguilera-Correa JJ.
PMID: 34204833
Antibiotics (Basel). 2021 Jun 12;10(6). doi: 10.3390/antibiotics10060711.

Fungal PJI is one of the most feared complications after arthroplasty. Although a rare finding, its high associated morbidity and mortality makes it an important object of study. The most frequent species causing fungal PJI is

Cite
Garlito-Díaz H, Esteban J, Mediero A, et al. A New Antifungal-Loaded Sol-Gel Can Prevent . Antibiotics (Basel). 2021;10(6)doi: 10.3390/antibiotics10060711.
Garlito-Díaz, H., Esteban, J., Mediero, A., Carias-Cálix, R. A., Toirac, B., Mulero, F., Faus-Rodrigo, V., Jiménez-Morales, A., Calvo, E., & Aguilera-Correa, J. J. (2021). A New Antifungal-Loaded Sol-Gel Can Prevent . Antibiotics (Basel, Switzerland), 10(6), . https://doi.org/10.3390/antibiotics10060711
Garlito-Díaz, Hugo, et al. "A New Antifungal-Loaded Sol-Gel Can Prevent ." Antibiotics (Basel, Switzerland) vol. 10,6 (2021). doi: https://doi.org/10.3390/antibiotics10060711
Garlito-Díaz H, Esteban J, Mediero A, Carias-Cálix RA, Toirac B, Mulero F, Faus-Rodrigo V, Jiménez-Morales A, Calvo E, Aguilera-Correa JJ. A New Antifungal-Loaded Sol-Gel Can Prevent . Antibiotics (Basel). 2021 Jun 12;10(6). doi: 10.3390/antibiotics10060711. PMID: 34204833; PMCID: PMC8231561.
Copy Download .nbib Format: NLM
Antifungal drugs work together to treat germs causing fungal infections.

Future microbiology

Pfaller MA, Messer SA, Deshpande LM, Rhomberg PR, Utt EA, Castanheira M.
PMID: 34184545
Future Microbiol. 2021 Jul;16:765-768. doi: 10.2217/fmb-2021-0086. Epub 2021 Jun 29.

Life-threatening infections can be caused by a fungus called

Cite
Pfaller MA, Messer SA, Deshpande LM, et al. Antifungal drugs work together to treat germs causing fungal infections. Future Microbiol. 2021;16:765-768doi: 10.2217/fmb-2021-0086.
Pfaller, M. A., Messer, S. A., Deshpande, L. M., Rhomberg, P. R., Utt, E. A., & Castanheira, M. (2021). Antifungal drugs work together to treat germs causing fungal infections. Future microbiology, 16765-768. https://doi.org/10.2217/fmb-2021-0086
Pfaller, Michael A, et al. "Antifungal drugs work together to treat germs causing fungal infections." Future microbiology vol. 16 (2021): 765-768. doi: https://doi.org/10.2217/fmb-2021-0086
Pfaller MA, Messer SA, Deshpande LM, Rhomberg PR, Utt EA, Castanheira M. Antifungal drugs work together to treat germs causing fungal infections. Future Microbiol. 2021 Jul;16:765-768. doi: 10.2217/fmb-2021-0086. Epub 2021 Jun 29. PMID: 34184545.
Copy Download .nbib Format: NLM
Evaluation of the .

Frontiers in microbiology

Zhang Y, Liu YC, Chen SM, Zong H, Hou WT, Qiu XR, Guo SY, Sun YF, Jiang YY, An MM, Shen H.
PMID: 34970244
Front Microbiol. 2021 Dec 14;12:788442. doi: 10.3389/fmicb.2021.788442. eCollection 2021.

Recent decades have seen a significant increase in invasive fungal infections, resulting in unacceptably high mortality rates. Anidulafungin (AN) is the newest echinocandin and appears to have several advantages over existing antifungals. However, its poor water solubility and burdensome...

Cite
Zhang Y, Liu YC, Chen SM, et al. Evaluation of the . Front Microbiol. 2021;12:788442doi: 10.3389/fmicb.2021.788442.
Zhang, Y., Liu, Y. C., Chen, S. M., Zong, H., Hou, W. T., Qiu, X. R., Guo, S. Y., Sun, Y. F., Jiang, Y. Y., An, M. M., & Shen, H. (2021). Evaluation of the . Frontiers in microbiology, 12788442. https://doi.org/10.3389/fmicb.2021.788442
Zhang, Yu, et al. "Evaluation of the ." Frontiers in microbiology vol. 12 (2021): 788442. doi: https://doi.org/10.3389/fmicb.2021.788442
Zhang Y, Liu YC, Chen SM, Zong H, Hou WT, Qiu XR, Guo SY, Sun YF, Jiang YY, An MM, Shen H. Evaluation of the . Front Microbiol. 2021 Dec 14;12:788442. doi: 10.3389/fmicb.2021.788442. eCollection 2021. PMID: 34970244; PMCID: PMC8712755.
Copy Download .nbib Format: NLM
Evaluation of the .

Frontiers in microbiology

Zhang Y, Liu YC, Chen SM, Zong H, Hou WT, Qiu XR, Guo SY, Sun YF, Jiang YY, An MM, Shen H.
PMID: 34970244
Front Microbiol. 2021 Dec 14;12:788442. doi: 10.3389/fmicb.2021.788442. eCollection 2021.

Recent decades have seen a significant increase in invasive fungal infections, resulting in unacceptably high mortality rates. Anidulafungin (AN) is the newest echinocandin and appears to have several advantages over existing antifungals. However, its poor water solubility and burdensome...

Cite
Zhang Y, Liu YC, Chen SM, et al. Evaluation of the . Front Microbiol. 2021;12:788442doi: 10.3389/fmicb.2021.788442.
Zhang, Y., Liu, Y. C., Chen, S. M., Zong, H., Hou, W. T., Qiu, X. R., Guo, S. Y., Sun, Y. F., Jiang, Y. Y., An, M. M., & Shen, H. (2021). Evaluation of the . Frontiers in microbiology, 12788442. https://doi.org/10.3389/fmicb.2021.788442
Zhang, Yu, et al. "Evaluation of the ." Frontiers in microbiology vol. 12 (2021): 788442. doi: https://doi.org/10.3389/fmicb.2021.788442
Zhang Y, Liu YC, Chen SM, Zong H, Hou WT, Qiu XR, Guo SY, Sun YF, Jiang YY, An MM, Shen H. Evaluation of the . Front Microbiol. 2021 Dec 14;12:788442. doi: 10.3389/fmicb.2021.788442. eCollection 2021. PMID: 34970244; PMCID: PMC8712755.
Copy Download .nbib Format: NLM
Showing 85 to 94 of 94 entries